From disease-modifying medications to rehabilitation strategies, choosing treatment for multiple sclerosis starts with understanding your options. Take an active role in managing your care. Verywell ...

Multiple sclerosis (MS ... turn to nonpharmaceutical treatments when conventional treatments don’t work to improve their symptoms. Others decide to try these options when their healthcare ...

These approvals subsequently triggered intense pharmaceutical research, leading to the numerous options available ... aiding in the development of more reliable treatment algorithms.

Our providers work together. They understand the full range of treatment options, so they can tailor a care plan to your exact needs. There is no single test for multiple sclerosis. Experts diagnose ...

Nevertheless, approval by WHO of the MSIF application will be a crucial first step to ensure that people with multiple sclerosis will be able to access appropriate treatment options in LMICs.

If you've been diagnosed with multiple sclerosis (MS), it's time to start exploring treatment options. You've got a lot of them, everything from disease-modifying therapies and drugs that help manage ...

Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the protective myelin sheaths that surround nerve fibres, leading to neurological disturbances. Autologous ...

1 Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Cardiff, UK Background A minority of patients with multiple sclerosis (MS) have ...

Multiple sclerosis (MS) is a long-lasting (chronic ... Eye exam and visual fields measurements. Treatment will depend on your symptoms, age, and general health. It will also depend on how bad the ...

Newly published research in the journal Gliahas identified crucial links between dietary choices and the progression of ...

uhbs.ch Objective The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) in patients with ...